OBJECTIVE: Due to contradictory results of previous studies evaluating the association between ischemic stroke (IS) and thrombophilic polymorphisms, their routine screening in IS patients, particularly those older than 60 years, is not recommended. We evaluated the differences in the distribution of rs6025 and rs1799963 polymorphisms according to IS subtypes and their interaction with smoking. METHODS: We conducted a case-control study of 423 hospital-based consecutive survivors of their first-ever IS and 614 population-based controls. Survivors (18-81 years) with IS documented by brain imagining were examined at a median of 16 months after the index event. The stroke subtype was categorized using the Causative Classification of Stroke System. Controls (50-75 years) were free of a history of stroke/TIA, coronary heart disease, and venous thromboembolism. RESULTS: Age- and gender-adjusted prevalence of individuals carrying at least one copy of the rs1799963A minor allele was 5.3% among stroke survivors (by subtypes: 3.1% in large artery atherosclerosis, 2.0% in cardio-aortic embolism, 2.4% in small artery occlusion, and 10.3% in undetermined stroke) vs. 2.4% among controls. In multinomial multivariate adjusted analysis, rs1799963 was exclusively associated with undetermined stroke (OR: 3.67; 95% CI: 1.52-8.85; p = 0.004). There was strong evidence of rs1799963 × smoking synergistic interaction (OR: 5.14; 95% CI: 1.65-16.01; p = 0.005). There was no association of rs6025 with IS in general, or with any subtype. CONCLUSIONS: In our consecutive IS survivors, carriage of the rs1799963A allele is associated with undetermined stroke. This effect appears to be confined to smokers.

• MeSH
• Stroke diagnosis   epidemiology   genetics   MeSH
• Adult MeSH
• Phenotype MeSH
• Gene Frequency MeSH
• Genetic Predisposition to Disease MeSH
• Heterozygote MeSH
• Risk Assessment MeSH
• Homozygote MeSH
• Brain Ischemia diagnosis   epidemiology   genetics   MeSH
• Smoking adverse effects   epidemiology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Logistic Models MeSH
• Adolescent MeSH
• Young Adult MeSH
• Multivariate Analysis MeSH
• Odds Ratio MeSH
• Polymorphism, Genetic * MeSH
• Prevalence MeSH
• Prothrombin genetics   MeSH
• Risk Factors MeSH
• Chi-Square Distribution MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Case-Control Studies MeSH
• Thrombophilia blood   complications   diagnosis   epidemiology   genetics   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Young Adult MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Geographicals
• Czech Republic MeSH

• Publication type
• Meeting Abstract MeSH

The primary aim was to determine frequencies of mutations related to risk of venous thrombosis in healthy Caucasians in Central Bohemia. In a cohort of 1527 healthy individuals the frequency of risk alleles for the mutations FV Leiden and FII 20210G>A was 4.5% and 1.3%, respectively. Frequency of 4G PAI-1 allele was 55.5%. Genotype frequencies were: GG 91.03%, GA 8.91%, and AA 0.07% for FV Leiden; GG 97.45%, GA 2.49%, and AA 0.07% for FII 20210G>A; 4G/4G 30.26%, 4G/5G 50.56%, and 5G/5G 19.19% for PAI-1. Frequency of the risk allele A in polymorphism SERPINC1 (IVS +141G >A) was 11.3%, and frequencies of genotypes were as follows: GG 78.36%, GA 20.66%, and AA 0.98%. Frequency of the risk allele T for polymorphism GP6 13254T>C was 87.7%, and frequencies of genotypes were as follows: TT 77.14%, TC 21.15%, and CC 1.70%. Frequency of the risk allele A in polymorphism CYP4V2 (Lys259Gln) was 65.2%, and frequencies of genotypes were: CC 12.25%, CA 45.12 %, and AA 42.63%. All observed genotypes and alleles frequencies were without gender differences. Their occurrences confirm a relatively high prevalence of hereditary thrombophilia predisposition in the Czech Republic.

• MeSH
• Adult MeSH
• Gene Frequency genetics   MeSH
• Cohort Studies MeSH
• Humans MeSH
• Mutation genetics   MeSH
• Venous Thrombosis diagnosis   epidemiology   genetics   MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Geographicals
• Czech Republic MeSH

Východisko. Faktor V Leiden (G1691A) či mutace genu pro protrombin FII G20210A jsou nezávislé rizikové faktory žilní trombózy a kombinovaný výskyt genotypu 4G/4G PAI-1 ještě toto riziko zvyšuje. Cíl. Primárním cílem bylo zjistit frekvenci minoritních alel a genotypů FVL, FII G20210A a PAI-1 4G/5G u zdravých osob kavkazské rasy v Praze a v regionu středních Čech. Druhotným cílem bylo zjistit výskyt jejich vzájemných kombinací. Metody. Genotypizace byla provedena u 1450 zdravých osob (dárců krve, 981 mužů a 469 žen) pomocí robotické izolace DNA a následnou amplifikací PCR s analýzou křivky tání (Light Cycler 480 System, Roche). Výsledky. Frekvence minoritních alel mutací FV Leiden a FII G20210A byla 4,5 %, respektive 1,3 %. Frekvence alely 4G PAI-1 byla 55,9 %. Frekvence genotypů byly: GG 91,10 %, GA 8,83 % a AA 0,07 % pro FV Leiden; GG 97,38 %, GA 2,55 % a AA 0,07 % pro FII G20210A a 4G/4G 30,69 %, 4G/5G 50,34 % a 5G/5G 18,97 % pro PAI-1. U obou pohlaví se tyto frekvence nelišily. Kombinace heterozygotní mutace FII s heterozygotní mutací FV Leiden se vyskytovala v 0,14 %. Kombinace genotypu PAI-1 4G/4G s heterozygotní mutací FV Leiden se vyskytovala v 2,83 % a s heterozygotní mutací FII v 0,62 %. Závěry. Zjištěné frekvence genotypů a alel potvrzují relativně vysokou prevalenci hereditárních trombofilií v České republice.

Background. Factor V Leiden (G1691A) and prothrombin gene (FII G20210A) mutations are independent risk factors of venous thrombosis and this risk is further increased by the combined genotype 4G/4G PAI-1. Aim. The primary objective was to identify the frequency of mutations of minor alleles and genotypes of FVL, FII G20210A and PAI-1 4G/5G in healthy Caucasians in the Prague and Central Bohemia regions. The secondary objective was to identify the occurrence of their mutual combinations. Method. Genotyping was performed in 1,450 healthy individuals (blood donors, 981 men and 469 women) using robotic DNA isolation and subsequent PCR and melting curve analysis (Light Cycler 480 System, Roche). Results. The minor allele frequencies in FV Leiden and FII G20210A mutations were 4.5 % and 1.3% respectively. The frequency of the 4G PAI-1 allele was 55.9%. The genotype frequencies were as follows: GG 91.10%, GA 8.83% and AA 0.07% for FV Leiden; GG 97.38%, GA 2.55% and AA 0.07% for FII G20210A and 4G/4G 30.69%, 4G/5G 50.34% and 5G/5G 18.97% for PAI-1. No differences in these frequencies were found between the genders. The occurrence of the combined heterozygous FII and heterozygous FV Leiden mutations was 0.14%. The PAI-1 4G/4G genotype was combined with the heterozygous FV Leiden mutation in 2.83% of cases and with the heterozygous FII mutation in 0.62% of cases. Conclusions. The found frequencies of genotypes and alleles confirm a relatively high prevalence of hereditary thrombophilia in the Czech Republic.

• MeSH
• Alleles MeSH
• Adult MeSH
• Financing, Organized MeSH
• Genotype MeSH
• Data Interpretation, Statistical MeSH
• Cohort Studies MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Young Adult MeSH
• Mutation MeSH
• Prevalence MeSH
• Activated Protein C Resistance genetics   MeSH
• Statistics as Topic MeSH
• Thromboembolism genetics   MeSH
• Thrombophilia genetics   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Young Adult MeSH
• Male MeSH
• Female MeSH
• Geographicals
• Czech Republic MeSH

Cíl: Primárním cílem bylo zjistit frekvenci alel a genotypů nových polymorfizmů spojovaných podle GWAS studií s výskytem žilní trombózy u zdravých osob kavkazské rasy v regionu středních Čech. Metody: Genotypizace trombofilních mutací SERPINC1 IVS +141G>A, GP6 13254T>C a CYP4V2 (Lys259Gln) byla provedena u 1 527 zdravých osob pomocí robotické izolace DNA a následnou amplifikací PCR s analýzou křivky tání (LightCycler 480 System, Roche). Výsledky: Frekvence rizikové alely A polymorfizmu SERPINC1 (IVS +141G>A) byla u sledovaného souboru 11,3 % a frekvence genotypů byla GG 78,36 %, GA 20,66 % a AA 0,98 %. Frekvence rizikové alely T polymorfizmu GP6 13254T>C byla 87,7 % a frekvence genotypů TT 77,14 %, TC 21,15 % a CC 1,70 %. Frekvence rizikové alely A polymorfizmu CYP4V2 (Lys259Gln) byla 65,2 % a frekvence genotypů CC 12,25 %, CA 45,12 % a AA 42,63 %. U obou pohlaví se tyto frekvence nelišily. Závěr: Zjištěné frekvence genotypů a alel potvrzují relativně vysokou prevalenci dalších hereditárních trombofilií v regionu střední Čechy. Jejich klinický význam však zatím není plně znám.

Objective: The aim of study was to determine frequencies of alleles and genotypes of new thrombophilia polymorhisms associated according to GWAS studies with venous thrombosis in Caucasian healthy people in Central Bohemia. Methods: Genotyping of thrombophilic mutations SERPINC1 IVS +141G>A, GP6 13254T>C and CYP4V2 (Lys259Gln) was performed in 1,527 healthy subjects using a robotic DNA isolation and subsequent PCR amplification with melting curve analysis (LightCycler480 System, Roche). Results: For the reference group was the frequency of risk allele A of SERPINC1 (IVS +141G>A) polymorphism 11.3% and frequencies of genotypes were GG 78.36%, GA 20.66% and AA 0.98%. Frequency of risk allele T of GP6 13254T>C polymorphism was 87.7% and frequencies of genotypes were TT 77.14%, TC 21.15% and CC 1.70%. Frequency of risk allele A of CYP4V2 polymorphism (Lys259Gln) was 65.2% and frequencies of genotypes were CC 12.25%, CA 45.12% and AA 42.63%. Those frequencies were not differ for both genders. Conclusion: The results confirm relatively high prevalence of other hereditary thrombophilia polymorphisms in Central Bohemia. But their clinical significance is not fully known yet.

• Keywords
• SERPINC1 (IVS +141G>A), GP6 (13254T>C), CYP4V2 (Lys259Gln),
• MeSH
• Blood Donors MeSH
• Adult MeSH
• Genotyping Techniques * methods   MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Antithrombin III Deficiency * genetics   MeSH
• Polymorphism, Genetic genetics   MeSH
• Prevalence MeSH
• Risk Factors * MeSH
• Cytochrome P-450 Enzyme System genetics   MeSH
• Thrombophilia * epidemiology   genetics   MeSH
• Venous Thrombosis * epidemiology   genetics   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Male MeSH
• Female MeSH

Úvod: Je známo, že polymorfi smy v genech cytochromu P 450 2C9 a reduktázy epoxidu vitaminu K, podjednotky 1 (VKORC1) ovlivňují senzitivitu na warfarin. Cíl studie: Chtěli jsme zjistit prevalenci polymorfi smů CYP2C9 (alel *1, *2 a *3) a VKORC1 (alel G a A v pozici -1639) a jejich kombinací v naší populaci, abychom získali představu, kolika procent jedinců se zvýšená senzitivita na warfarin teoreticky může týkat. Metody: Genotypizace byla provedena u 1 300 zdravých osob (774 mužů a 526 žen) pomocí robotické izolace DNA a následnou amplifi kací PCR s analýzou křivky tání (Light Cycler 480 System, Roche). Výsledky: Kombinace genotypů VKORC1 -1639 A/A spolu s CYP2C9 *1/*3, *2/*2, *2/*3, *3/*3 a vzácná kombinace VKORC1 -1639 G/A s CYP2C9 *3/*3, které podmiňují velmi vysokou senzitivitu na warfarin, byly určeny u 1,6 % osob. Kombinace VKORC1 -1639 A/A spolu s CYP2C9 *1/*2, VKORC1 -1639 G/A spolu s CYP2C9 *2/*3 a VKORC1 -1639 G/G spolu s CYP2C9 *3/*3, které podmiňují vysokou senzitivitu na warfarin, byly určeny u 3,3 % osob a kombinace VKORC1 -1639 A/A spolu s CYP2C9 *1/*1, VKORC1 -1639 G/A spolu s CYP2C9 *1/*2, *1/*3, *2/*2 a VKORC1 -1639 G/G spolu s CYP2C9 *2/*3, které podmiňují středně vysokou senzitivitu na warfarin, byly určeny u 26,2 % osob. Závěr: Asi 30 % zdravých osob v české populaci má geneticky podmíněnou vyšší senzitivitu na warfarin. Jako alternativa warfarinu jsou diskutována nová antitrombotika.

Introduction: Polymorphisms in the genes encoding the cytochrome P 450 2C9 enzyme and the vitamin K epoxide reductase, subunit 1 (VKORC1) are known to contribute to the sensitivity to warfarin. Aim of the study: We wanted to determine the prevalence of CYP2C9 (allele *1, *2 and *3) and VKORC1 (-1639 G and A alleles), and their combinations in Czech population to get an idea of how many percent of individuals can theoretically involve increased sensitivity to warfarin. Methods: Genotyping was performed in 1300 healthy subjects (774 men and 526 women) using a robotic DNA isolation and subsequent PCR amplifi cation according to the manufacturer’s instructions with melting curve analysis (Light Cycler 480 System, Roche). Results: The combinations of VKORC1 -1639 A/A genotypes with CYP2C9 *1/*3, *2/*2, *2/*3 or *3/*3, and a rare combination of VKORC1 -1639 G/A with CYP2C9 *3/*3, which underlie very high sensitivity to warfarin, were determined in 1.6% of people. The combinations of VKORC1 -1639 A/A with CYP2C9 *1/*2, VKORC1 -1639 G/A with CYP2C9 *2/*3, and VKORC1 -1639 G/G with CYP2C9 *3/*3, which underlie high sensitivity to warfarin, were determined in 3.3% of people. The combinations of VKORC1 -1639 A/A with CYP2C9 *1/*1, and VKORC1 -1639 G/A with the CYP2C9 *1/*2, *1/*3, *2/*2 or VKORC1 -1639 G/G with CYP2/C *2/*3, which underlie medium-high sensitivity to warfarin, were determined in 26.2% of people. Conclusion: About 30% of the Czech healthy subjects have genetically determined higher sensitivity to warfarin. New antithrombotics use is discussed as an alternative to warfarin.

• Keywords
• Nová antitrombotika,
• MeSH
• Aryl Hydrocarbon Hydroxylases genetics   drug effects   MeSH
• Molecular Diagnostic Techniques utilization   MeSH
• Financing, Organized MeSH
• Genotype MeSH
• Platelet Aggregation Inhibitors administration & dosage   pharmacokinetics   adverse effects   MeSH
• Hemorrhage genetics   chemically induced   MeSH
• Humans MeSH
• Mixed Function Oxygenases genetics   drug effects   MeSH
• Polymorphism, Genetic genetics   drug effects   MeSH
• Prevalence MeSH
• Cytochrome P-450 Enzyme System genetics   MeSH
• Dose-Response Relationship, Drug MeSH
• Warfarin administration & dosage   pharmacokinetics   adverse effects   MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Female MeSH
• Geographicals
• Czech Republic MeSH

• Publication type
• Meeting Abstract MeSH

AIM: The purpose of this study was to asses the impact of haemostatic and platelet receptor gene polymorphisms as an inherited risk factor for premature onset of myocardial infarction (MI). METHODS: Polymorphisms of platelet receptors - GP Ia (807C>T, rs1126643), GP VI (13254T>C, rs1613662), GP IIIa (HPA-1, rs5918), PAR -1 (IVS -14A>T; rs168753), P2Y(12) (34C>T, rs6785930 and H1/H2 haplotype, rs2046934), and genetic variations of the gene coding for cyclooxygenase-1 (COX-1) ( -842A>G, rs10306114 and 50C>T, rs3842787) were investigated. Mutations in the genes coding for coagulation factor V (Q506R (Leiden) mutation, rs6025) and factor II (prothrombin G20210A, rs1799963) were also determined. The prevalence of gene polymorphisms was investigated in 105 consecutive patients with premature MI. This was compared with the same gene polymorphism prevalence in a group of 132 patients in which coronary artery disease had been excluded. Genotyping was done using PCR, followed by melting curve analysis with specific fluorescent hybridization probes. RESULTS: A significant association between GP VI 13254C allele carriers and premature MI was found (p=0.025). No other differences in prevalence of the investigated polymorphisms between the compared patient populations reached statistical significance. In a logistic regression, which took other cardiovascular risk factors into account, the significance of the GP VI 13254C allele and vascular risk was suggested (OR 1.888, 95% C.I. 1.029 to 3.464, p=0.040). In a binary logistic regression the positive relationship between the GP VI genotype and female gender was observed (0R 3.676; 95% C.I. 1.159 to 11.628; p=0.027). The frequencies of GP VI and GP Ia gene polymorphisms were independent of one another (p=0.836). CONCLUSION: The presence of the GP VI 13254C allele is an independent predictor of premature MI.

• MeSH
• Alleles MeSH
• Adult MeSH
• Gene Frequency MeSH
• Genotype MeSH
• Platelet Membrane Glycoproteins analysis   genetics   MeSH
• Myocardial Infarction genetics   MeSH
• Middle Aged MeSH
• Humans MeSH
• Logistic Models MeSH
• Polymorphism, Genetic MeSH
• Randomized Controlled Trials as Topic MeSH
• Risk Factors MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

AIM: Utilization of cardiac catheterization has increased dramatically over time. Bleeding is a major prognostic predictor after percutaneous coronary catheterization procedures. This study aimed to assess the impact of eight polymorphisms of genes encoding platelet receptors and enzymes on the risk of bleeding in patients undergoing elective coronary angiography (CAG). METHODS: Polymorphisms of platelet receptors, GP Ia (807C>T, rs1126643), GP VI (13254T>C, rs1613662), GP IIIa (HPA-1, rs5918), PAR-1 (IVS-14A>T, rs168753), P2Y(12) (34C>T, rs6785930 and H1/H2 haplotype, rs2046934), and genetic variations of the gene coding for cyclooxygenase-1 (COX-1) (-842A>G, rs10306114 and 50C>T, rs3842787) were studied. The frequencies of gene polymorphisms carriers were investigated in 696 patients undergoing elective CAG because of suspected or proven stable coronary artery disease. Genotyping was done using PCR, followed by melting curve analysis with specific fluorescent hybridization probes. RESULTS: In patients undergoing elective CAG (without ad hoc percutaneous coronary intervention (PCI) and without clopidogrel pretreatment) a significant association was found between bleeding risk and variations in the gene coding for COX-1 (-842A>G and 50C>T) (both p=0.013). Six other investigated polymorphisms did not show any influence on bleeding complications. After controlling for potential bleeding confounders, the association between COX-1 gene polymorphisms (-842A>G and 50C>T) and bleeding risk remained statistically significant (both odds ratios 12.1, p=0.012). CONCLUSION: Cyclooxygenase-1 -842G and 50T alleles significantly contribute to the risk of bleeding complications in patients undergoing elective CAG. Genetic testing is able to influence the safety of diagnostic cardiac catheterization in large numbers of low risk patients with borderline indications.

• MeSH
• Prostaglandin-Endoperoxide Synthases genetics   MeSH
• Genotype MeSH
• Nucleic Acid Hybridization MeSH
• Polymorphism, Single Nucleotide MeSH
• Catheterization MeSH
• Coronary Angiography methods   MeSH
• Hemorrhage MeSH
• Middle Aged MeSH
• Humans MeSH
• Polymorphism, Genetic MeSH
• Risk MeSH
• Aged MeSH
• Blood Platelets cytology   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Clinical Trial MeSH
• Research Support, Non-U.S. Gov't MeSH

Cílem naší studie bylo zjistit frekvenci výskytu destickových polymor?smu, které jsou spojovány s aterotrombogenezí u zdravých osob stredního veku v ceské populaci. Metody: K zjištení frekvence polymor?smu GP IIIa (HPA-1; rs5918), P2Y12 (H1/H2 haplotyp; rs2046934), P2Y12 (34C > T; rs6785930), COX-1 (-842A > G; rs10306114), PAR-1 (IVS -14A > T; rs168753), GP VI (13254T > C; rs1613662) a GP Ia (807C > T; rs1126643) bylo provedeno anonymní testování DNA od 1 450 dárcu krve pomocí PCR (polymerázové retezové reakce) a analýzy krivky tání na analyzátoru LightCycler 480 (ROCHE). Výsledky: V testované skupine byly zjišteny tyto frekvence; GP IIIa (HPA-1): 27,38 % heterozygotu, 3,66 % homozygotu a 68,97 % „wild type“ homozygotu; P2Y12 (H1/H2 haplotyp): 25,93 % heterozygotu, 2,62 % homozygotu a 71,45 % „wild type“ homozygotu; P2Y12 (34C > T): 44,03 % heterozygotu, 9,69 % homozygotu a 46,28 % „wild type“ homozygotu; COX-1 (-842A > G): 12,00 % heterozygotu, 0,41 % homozygotu a 87,59 % „wild type“ homozygotu; PAR-1 (IVS -14A > T): 28,55 % heterozygotu, 4,41 % homozygotu a 67,03 % „wild type“ homozygotu; GP VI (13254T > C): 21,45 % heterozygotu, 1,79 % homozygotu a 76,76 % „wild type“ homozygotu; GP Ia (807C > T): 47,27 % heterozygotu, 16,70 % homozygotu a 36,02 % „wild type“ homozygotu. Záver: V Ceské republice byla zjištena 10–40% frekvence testovaných polymor?smu desticek v populaci zdravých osob stredního veku, které jsou spojovány s náchylností k aterotrombogenezi nebo nedostatecnému úcinku protidestickové lécby.

The aim of our study was to assess the frequencies of platelet gene polymorphisms associated with atherothrombogenesis in the healthy middle-aged Czech population. Methods: Anonymous testing of 1,450 blood donor DNA by PCR followed by melting curve analysis using a LightCycler 480 analyzer (ROCHE) were used to determine the frequencies of GP IIIa (HPA-1; rs5918), P2Y12 (H1/H2 haplotyp; rs2046934), P2Y12 (34C > T; rs6785930), COX-1 (-842A > G; rs10306114), PAR-1 (IVS -14A > T; rs168753), GP VI (13254T > C; rs1613662) and GP Ia (807C > T; rs1126643) polymorphisms. Results: The frequencies of GP IIIa (HPA-1) were: 27.38% of heterozygotes, 3.66% of homozygotes, and 68.97% of “wild type“ homozygotes; frequencies of P2Y12 (H1/H2 haplotype) were: 25.93% of heterozygotes, 2.62% of homozygotes, and 71.45% of “wild type“ homozygotes; frequencies of P2Y12 (34C > T) were: 44.03% of heterozygotes, 9.69% of homozygotes and 46.28% of “wild type“ homozygotes; frequencies of COX-1 (-842A > G) were: 12.00% of heterozygotes, 0.41% of homozygotes, and 87.59% of “wild type“ homozygotes; frequencies of PAR-1 (IVS -14A > T) were: 28.55% of heterozygotes, 4.41% of homozygotes, and 67.03% of “wild type“ homozygotes, frequencies of GP VI (13254T > C) were: 21.45% of heterozygotes, 1.79% of homozygotes, and 76.76% of “wild type“ homozygotes; frequencies of GP Ia (807C > T) were: 47.27% of heterozygotes, 16.70% of homozygotes, and 36.02% of “wild type“ homozygotes in the tested group of healthy persons. Conclusion: The frequencies of tested platelets gene polymorphisms implicated in in=uencing susceptibility to atherothrombogenesis, or to failure of antiplatelet therapy, were 10–40% in the healthy middle-aged Czech population.

• MeSH
• Platelet Aggregation physiology   MeSH
• Atherosclerosis etiology   genetics   MeSH
• Adult MeSH
• Epidemiologic Studies MeSH
• Platelet Aggregation Inhibitors metabolism   MeSH
• Integrin alphaVbeta3 genetics   MeSH
• Integrin beta3 genetics   MeSH
• Middle Aged MeSH
• Humans MeSH
• Polymorphism, Genetic MeSH
• Platelet Glycoprotein GPIIb-IIIa Complex genetics   MeSH
• Thrombosis etiology   genetics   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Geographicals
• Czech Republic MeSH